Vital Therapies, Inc. (NASDAQ:VTL) has received an average rating of “Hold” from the six research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $8.00.

A number of research firms have weighed in on VTL. Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/vital-therapies-inc-vtl-receives-8-00-consensus-target-price-from-brokerages/1618275.html.

Shares of Vital Therapies (NASDAQ:VTL) traded down 2.48% during trading on Thursday, hitting $5.90. 114,303 shares of the stock were exchanged. The firm has a 50 day moving average price of $4.08 and a 200 day moving average price of $3.43. Vital Therapies has a 52 week low of $2.25 and a 52 week high of $6.58. The firm’s market capitalization is $249.02 million.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01. During the same quarter in the prior year, the business earned ($0.30) EPS. Analysts forecast that Vital Therapies will post ($1.31) EPS for the current fiscal year.

In other Vital Therapies news, Director Muneer A. Satter bought 130,000 shares of Vital Therapies stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $4.01 per share, with a total value of $521,300.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 10,000 shares of Vital Therapies stock in a transaction on Wednesday, September 13th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $40,000.00. Following the completion of the acquisition, the director now directly owns 65,119 shares in the company, valued at $260,476. The disclosure for this purchase can be found here. Insiders have acquired a total of 190,000 shares of company stock worth $737,800 over the last three months. Insiders own 32.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Vital Therapies in the 1st quarter worth approximately $167,000. Goldman Sachs Group Inc. lifted its position in shares of Vital Therapies by 1.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after purchasing an additional 1,157 shares during the period. Susquehanna International Group LLP acquired a new position in shares of Vital Therapies in the 2nd quarter worth approximately $268,000. Blair William & Co. IL lifted its position in shares of Vital Therapies by 67.2% in the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after purchasing an additional 40,000 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Vital Therapies by 11.5% in the 1st quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after purchasing an additional 9,120 shares during the period. Hedge funds and other institutional investors own 25.58% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.